Spots Global Cancer Trial Database for stage iiia hepatocellular carcinoma ajcc v8

Every month we try and update this database with for stage iiia hepatocellular carcinoma ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer	NCT04605731	BCLC Stage B He... BCLC Stage C He... Locally Advance... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	Durvalumab Tremelimumab	18 Years -	City of Hope Medical Center
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver	NCT04175912	Metastatic Chol... Metastatic Hepa... Stage III Hepat... Stage III Intra... Stage IIIA Hepa... Stage IIIA Intr... Stage IIIB Hepa... Stage IIIB Intr... Stage IV Hepato... Stage IV Intrah... Stage IVA Hepat... Stage IVB Hepat... Unresectable Ch... Unresectable He... Unresectable In...	Carboplatin Paclitaxel Pevonedistat	18 Years -	National Cancer Institute (NCI)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	NCT05092373	Advanced Breast... Advanced Endome... Advanced Fallop... Advanced Hepato... Advanced Malign... Advanced Malign... Advanced Malign... Advanced Ovaria... Advanced Primar... Advanced Renal ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Malignant Abdom... Malignant Solid... Metastatic Brea... Metastatic Endo... Metastatic Fall... Metastatic Hepa... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Metastatic Rena... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Fallo... Stage III Hepat... Stage III Ovari... Stage III Prima... Stage III Renal... Stage III Uteri... Stage IIIA Fall... Stage IIIA Hepa... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Hepa... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Fallop... Stage IV Hepato... Stage IV Ovaria... Stage IV Primar... Stage IV Renal ... Stage IV Uterin... Stage IVA Fallo... Stage IVA Hepat... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVB Fallo... Stage IVB Hepat... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Atezolizumab Cabozantinib S-... Nab-paclitaxel Tumor Treating ...	18 Years -	M.D. Anderson Cancer Center
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer	NCT03439891	Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IIIC Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat...	Nivolumab Sorafenib	18 Years -	University of California, San Francisco
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant	NCT05103904	Recurrent Hepat... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	Laboratory Biom... Lenvatinib	18 Years -	Emory University
Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma	NCT01176604	Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	Yttrium Y 90 Gl...	-	M.D. Anderson Cancer Center
An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer	NCT04022746	Advanced Adult ... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat...	Magnetic Resona... Magnetic Resona...	18 Years -	M.D. Anderson Cancer Center
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant	NCT05103904	Recurrent Hepat... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	Laboratory Biom... Lenvatinib	18 Years -	Emory University
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer	NCT03695250	Metastatic Hepa... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	IDO1 Inhibitor ... Nivolumab	18 Years -	University of California, Davis
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant	NCT05103904	Recurrent Hepat... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	Laboratory Biom... Lenvatinib	18 Years -	Emory University
Y-90 Versus SBRT for Inoperable HCC	NCT05157451	Hepatocellular ... Stage I Hepatoc... Stage IA Hepato... Stage IB Hepato... Stage II Hepato... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IVA Hepat...	Quality of Life Questionnaire A... Stereotactic Bo... Yttrium-90 Micr...	18 Years -	OHSU Knight Cancer Institute
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)	NCT03896646	Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	Computed Tomogr... Hepatobiliary I... Single Photon E... Yttrium Y 90 Gl... Yttrium-90 Micr...	18 Years -	M.D. Anderson Cancer Center
Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma	NCT01176604	Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	Yttrium Y 90 Gl...	-	M.D. Anderson Cancer Center
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer	NCT04380545	Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable Fi...	Fluorouracil Nivolumab Recombinant Int...	12 Years -	M.D. Anderson Cancer Center
Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma	NCT01176604	Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	Yttrium Y 90 Gl...	-	M.D. Anderson Cancer Center
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer	NCT03439891	Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IIIC Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat...	Nivolumab Sorafenib	18 Years -	University of California, San Francisco
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab	NCT05199285	BCLC Stage B He... BCLC Stage C He... Locally Advance... Metastatic Hepa... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	Ipilimumab Nivolumab	18 Years -	Academic and Community Cancer Research United
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer	NCT05194293	Stage IB Hepato... Stage II Hepato... Stage III Hepat... Stage IIIA Hepa...	Durvalumab Regorafenib	18 Years -	Academic and Community Cancer Research United
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer	NCT03695250	Metastatic Hepa... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	IDO1 Inhibitor ... Nivolumab	18 Years -	University of California, Davis
Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition	NCT04430452	Advanced Hepato... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat...	Durvalumab Hypofractionate... Tremelimumab	18 Years -	University of California, San Francisco

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: